Meeting
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Real-world characterization of patients with cancer admitted with immune-related adverse events (irAEs).
Authors
Lawson Eng
Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada
Lawson Eng, RuiQui Chen, Elliot Charles Smith, Sze Wah Samuel Chan, Katrina Hueniken, M. Catherine Brown, Habeeb Majeed, Kendra Ross, Diana Gray, Wei Xu, David Hogg, Srikala S. Sridhar, Adrian G. Sacher, Natasha B. Leighl, Monika K. Krzyzanowska, Geoffrey Liu, Marcus O. Butler
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune-related Adverse Events
Citation
J Clin Oncol 37, 2019 (suppl 8; abstr 82)
DOI
10.1200/JCO.2019.37.8_suppl.82
Abstract #
82
Poster Bd #
D7
Abstract Disclosures
Similar Posters
Poster
2019 ASCO-SITC Clinical Immuno-Oncology Symposium
Comparison of care patterns for hospitalized immune-related adverse events (irAEs) between melanoma patients on combination immune checkpoint inhibitor (ICI) therapy versus ICI monotherapy.
First Author: RuiQui Chen
Poster
2023 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitors in microsatellite unstable/mismatch repair-deficient advanced pancreatic adenocarcinoma: An AGEO European Cohort.
First Author: Lorenzo Pilla
Poster
2022 ASCO Annual Meeting
Physician awareness of immune-related adverse events from checkpoint inhibitors.
First Author: Ahmed Bilal Khalid
Poster
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
Efficacy and toxicities of immune checkpoint inhibitors (ICIs) in advanced melanoma: A single institution experience.
First Author: Karim Welaya